Heart failure & cardiomyopathies
Arrhythmias in Patients With Heart Failure Prescribed Dofetilide or Sotalol
Authors' conclusion
In patients with HF who are prescribed dofetilide or sotalol, the risk of VT, but not SCA, was increased.
Study context
- Population
- Medicare patients taking dofetilide or sotalol and non-users, by heart failure (HF) status, 2014–2016multinomial propensity matched
- Participants
- 26,176 / 33,304 / 580,249
- Exposure
- Dofetilide/sotalol use in HF with preserved ejection fraction (HFpEF) or HFrEF vs no HF
- HFrEFn = 26,176
- HFpEFn = 33,304
- No HFn = 580,249reference
- Outcome
- VT and sudden cardiac arrest (SCA)
Methodological detailspropensity-score matched, Medicare claims
- Propensity-score matched
- Medicare claims
Main finding
As reported in the abstract
HFpEF
- Ventricular tachycardia (VT)
- 166 (10.68%) of 1,554
- Sudden cardiac arrest (SCA)
- 16 (1.03%) of 1,554
HFrEF
- VT
- 543 (38.76%) of 1,401
- SCA
- 40 (2.86%) of 1,401
No HF
- VT
- 245 (5.06%) of 4,839
- SCA
- 13 (0.27%) of 4,839
Ventricular tachycardia (VT)
HFpEF166 (10.68%) of 1,554
HFrEF543 (38.76%) of 1,401
No HF245 (5.06%) of 4,839
Sudden cardiac arrest (SCA)
HFpEF16 (1.03%) of 1,554
HFrEF40 (2.86%) of 1,401
No HF13 (0.27%) of 4,839
Each group vs no HFHazard ratio (95% CI)
HFrEFoverall VT risk
7.00(6.10–8.02)
HFpEFoverall VT risk
1.99(1.70–2.32)
HFrEFVT risk with dofetilide/sotalol
1.53(1.07–2.20)
HFpEFVT risk with dofetilide/sotalol
2.34(1.11–4.95)
HFrEFoverall SCA risk
5.19(4.10–6.57)
HFpEFoverall SCA risk
2.53(1.98–3.23)
Observational data: associations, not effects.
Original publication
Arrhythmias in Patients With Heart Failure Prescribed Dofetilide or Sotalol. JACC Adv. Published 7 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →